Masterclass 3: Accelerating RNA Therapeutics from Design to In Vivo Validation: An Integrated End-to-End Platform

Accelerating RNA Therapeutics from Design to In Vivo Validation: An Integrated End-to-End Platform

This presentation will showcase Quantoom’s integrated, end-to-end platform for RNA-based technologies, enabling the rapid design, development, and production of both mRNA and self-amplifying RNA (saRNA) therapeutics and vaccines. The session will highlight how a fully streamlined approach—from antigen design to in vivo validation—can accelerate RNA program development and support translational decision-making.

Participants will gain insight into two case studies demonstrating the breadth and performance of the platform. The first features an internally developed H5N1 HPAI vaccine candidate, illustrating the complete workflow from mosaic sequence design through RNA production to in vivo challenge studies. The second, conducted in collaboration with a partner, focuses on a PPRV program in a sheep model, where advanced sequence optimization was used to design mRNA and saRNA candidates and benchmark their immunogenicity against commercially available lipid nanoparticle (LNP) systems.

Ashiqul Haque (Quantoom Biosciences)